245 related articles for article (PubMed ID: 21084819)
1. [Two cases of HER2-positive advanced or metastatic breast cancer, responding to lapatinib and capecitabine].
Nakamura Y; Aono T; Nomura M; Iwase K; Tanaka Y
Gan To Kagaku Ryoho; 2010 Nov; 37(11):2165-8. PubMed ID: 21084819
[TBL] [Abstract][Full Text] [Related]
2. [A case of breast cancer liver metastases responding to lapatinib and capecitabine therapy].
Sato T; Nakagawa T; Kuwayama T; Oda G; Sugimoto H; Ishiba T; Sugihara K
Gan To Kagaku Ryoho; 2011 Nov; 38(12):2180-2. PubMed ID: 22202322
[TBL] [Abstract][Full Text] [Related]
3. Lapatinib plus capecitabine resolved human epidermal growth factor receptor 2-positive brain metastases.
Glück S; Castrellon A
Am J Ther; 2009; 16(6):585-90. PubMed ID: 19287304
[TBL] [Abstract][Full Text] [Related]
4. [A case of stage IV breast cancer with large cancer ulcer responding to combination therapy of capecitabine and medroxyprogesterone acetate and cyclophosphamide].
Konishi K; Hasegawa N; Kaneko H; Iimura Y; Shoji Y; Kawabata M
Gan To Kagaku Ryoho; 2009 Sep; 36(9):1525-8. PubMed ID: 19755825
[TBL] [Abstract][Full Text] [Related]
5. [A case of effective trastuzumab plus gemcitabine therapy for human epidermal growth factor receptor 2-positive breast cancer].
Yabe N; Murai S; Shimizu H; Kitasato K; Yoshikawa T; Oto I; Nakadai J; Jinno H; Kitagawa Y
Gan To Kagaku Ryoho; 2013 Nov; 40(12):2396-8. PubMed ID: 24394124
[TBL] [Abstract][Full Text] [Related]
6. Rapid tumor shrinkage with lapatinib plus capecitabine in a patient with massive liver involvement.
Giotta F; Latorre A; Cramarossa A; Simone G; Florio C; Oliva S; Lorusso V
Tumori; 2013; 99(6):278e-81e. PubMed ID: 24503803
[TBL] [Abstract][Full Text] [Related]
7. Metastatic breast cancer treated with lapatinib with a prolonged benefit: a case report and a review of therapeutic options available.
Bianchi GV; Duca M; Sica L; Mariani G
Tumori; 2013; 99(6):269e-72e. PubMed ID: 24503801
[TBL] [Abstract][Full Text] [Related]
8. Unusual long-lasting cutaneous complete response to lapatinib and capecitabine in a heavily pretreated HER2-positive plurimetastatic breast cancer patient.
Pizzuti L; Sergi D; Barba M; Vici P
Tumori; 2013; 99(3):e127-30. PubMed ID: 24158082
[TBL] [Abstract][Full Text] [Related]
9. [A case of metastatic breast cancer with bilateral hydronephrosis effectively treated with capecitabine].
Yamauchi S; Nakagawa T; Kasahara M; Sugimoto H; Ishiba T; Tamura N; Nagahara M; Sato T; Sugihara K
Gan To Kagaku Ryoho; 2012 Nov; 39(12):2077-9. PubMed ID: 23267982
[TBL] [Abstract][Full Text] [Related]
10. Retreatment with trastuzumab after progression on lapatinib-based therapy in heavily pretreated HER2-positive metastatic breast cancer: a single-institution experience.
Carli P; Militello L; Miolo GM; Quitadamo D; Lombardi D; Torrisi E; Scalone S; Crivellari D; Spazzapan S
Tumori; 2014; 100(6):605-11. PubMed ID: 25688493
[TBL] [Abstract][Full Text] [Related]
11. Long-term disease control with lapatinib and capecitabine in a patient with HER2-positive metastatic breast cancer pretreated with trastuzumab and trastuzumab-emtansine.
De Angelis C; Milano M; Gargiulo P; Stanzione B; Forestieri V; Lauria R; Pensabene M; D'Arco F; De Placido S; Arpino G
Tumori; 2013; 99(3):e131-3. PubMed ID: 24158083
[TBL] [Abstract][Full Text] [Related]
12. [A case of elderly metastatic breast cancer with a complete response to treatment with capecitabine and cyclophosphamide].
Iida S; Furukawa K; Yokoyama T; Yanagihara K; Iwasaki R; Noguchi T; Tsuchiya S; Sugisaki Y; Naito Z; Tajiri T
Gan To Kagaku Ryoho; 2007 Oct; 34(10):1697-700. PubMed ID: 17940394
[TBL] [Abstract][Full Text] [Related]
13. Lapatinib-based therapy in heavily pretreated HER2-positive metastatic breast cancer: a single institution experience.
Crivellari D; Spazzapan S; Lombardi D; Militello L; Torrisi E; Russo AE; Sorio R; Talamini R; Miolo G; Carli P; Veronesi A
Tumori; 2012; 98(1):33-8. PubMed ID: 22495699
[TBL] [Abstract][Full Text] [Related]
14. Lapatinib plus capecitabine for HER2-positive advanced breast cancer: a multicentre study of Anatolian Society of Medical Oncology (ASMO).
Cetin B; Benekli M; Turker I; Koral L; Ulas A; Dane F; Oksuzoglu B; Kaplan MA; Koca D; Boruban C; Yilmaz B; Sevinc A; Berk V; Uncu D; Harputluoglu H; Coskun U; Buyukberber S
J Chemother; 2014 Oct; 26(5):300-5. PubMed ID: 24112786
[TBL] [Abstract][Full Text] [Related]
15. CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.
Pivot X; Manikhas A; Żurawski B; Chmielowska E; Karaszewska B; Allerton R; Chan S; Fabi A; Bidoli P; Gori S; Ciruelos E; Dank M; Hornyak L; Margolin S; Nusch A; Parikh R; Nagi F; DeSilvio M; Santillana S; Swaby RF; Semiglazov V
J Clin Oncol; 2015 May; 33(14):1564-73. PubMed ID: 25605838
[TBL] [Abstract][Full Text] [Related]
16. [Bi-weekly nab-paclitaxel and trastuzumab therapy effective against recurrent breast cancer with multiple lung metastases in elderly patient who had previously undergone two chemotherapeutic regimens for treatment of metastatic disease-a case Report].
Sakurai T; Jinta E; Suzuma T; Yoshimura G; Umemura T; Sakurai T
Gan To Kagaku Ryoho; 2012 Nov; 39(11):1703-6. PubMed ID: 23152023
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer.
Gajria D; Gonzalez J; Feigin K; Patil S; Chen C; Theodoulou M; Drullinsky P; D'Andrea G; Lake D; Norton L; Hudis CA; Traina TA
Breast Cancer Res Treat; 2012 Jan; 131(1):111-6. PubMed ID: 21898114
[TBL] [Abstract][Full Text] [Related]
18. 18FDG-PET for early prediction of complete response to lapatinib and capecitabine in HER2-positive metastatic breast cancer: a case report.
Riccardi F; Mocerino C; Barbato C; Vitale MG; Carrillo G; Trunfio M; Minelli S; Cartenì G
Tumori; 2013; 99(6):257e-60e. PubMed ID: 24503798
[TBL] [Abstract][Full Text] [Related]
19. [A case of HER2 overexpressing advanced breast cancer with CTF therapy [cyclophosphamide, pirarubicin (THPADM), fluorouracil] showed long-term effectiveness after paclitaxel shock].
Ikeda M; Sonoo H; Oota Y; Fujii S; Shimo T; Miyake A; Seki M; Nomura T; Yamamoto Y; Shiiki S; Nakashima K; Tanaka K; Kurebayashi J
Gan To Kagaku Ryoho; 2010 Dec; 37(13):2917-20. PubMed ID: 21160270
[TBL] [Abstract][Full Text] [Related]
20. Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer.
Welslau M; Diéras V; Sohn JH; Hurvitz SA; Lalla D; Fang L; Althaus B; Guardino E; Miles D
Cancer; 2014 Mar; 120(5):642-51. PubMed ID: 24222194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]